Chemomab Therapeutics (CMMB) Competitors $0.98 +0.01 (+1.03%) Closing price 08/6/2025 03:55 PM EasternExtended Trading$2.50 +1.52 (+155.10%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. PMVP, ARTV, QNTM, STRO, ASRT, GNTA, PYXS, MNOV, APLT, and OTLKShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include PMV Pharmaceuticals (PMVP), Artiva Biotherapeutics (ARTV), Quantum Biopharma (QNTM), Sutro Biopharma (STRO), Assertio (ASRT), Genenta Science (GNTA), Pyxis Oncology (PYXS), MediciNova (MNOV), Applied Therapeutics (APLT), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Its Competitors PMV Pharmaceuticals Artiva Biotherapeutics Quantum Biopharma Sutro Biopharma Assertio Genenta Science Pyxis Oncology MediciNova Applied Therapeutics Oncobiologics Chemomab Therapeutics (NASDAQ:CMMB) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Is CMMB or PMVP more profitable? PMV Pharmaceuticals' return on equity of -32.54% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -106.70% -82.18% PMV Pharmaceuticals N/A -32.54%-29.59% Which has more risk and volatility, CMMB or PMVP? Chemomab Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Do insiders & institutionals believe in CMMB or PMVP? 46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, CMMB or PMVP? Chemomab Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$13.94M-$0.76-1.29PMV PharmaceuticalsN/AN/A-$58.71M-$1.18-1.29 Do analysts prefer CMMB or PMVP? Chemomab Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 767.35%. PMV Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 261.84%. Given Chemomab Therapeutics' higher possible upside, research analysts plainly believe Chemomab Therapeutics is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CMMB or PMVP? In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 0.00 equaled PMV Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPMV Pharmaceuticals beats Chemomab Therapeutics on 5 of the 9 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.29M$3.01B$5.56B$9.47BDividend YieldN/A2.41%4.31%4.17%P/E Ratio-1.2916.5729.3723.99Price / SalesN/A313.98444.7496.71Price / CashN/A42.1735.8458.51Price / Book1.367.818.085.58Net Income-$13.94M-$54.52M$3.26B$265.35M7 Day Performance-8.41%0.41%0.44%-0.07%1 Month Performance-14.78%9.93%4.82%1.76%1 Year Performance-2.00%15.18%30.27%25.39% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics2.1658 of 5 stars$0.98+1.0%$8.50+767.3%-5.8%$18.29MN/A-1.2920Gap UpPMVPPMV Pharmaceuticals2.8087 of 5 stars$1.43-0.8%$5.50+285.2%+0.7%$73.77MN/A-1.2050News CoverageUpcoming EarningsARTVArtiva Biotherapeutics2.318 of 5 stars$3.03+0.5%$17.80+488.4%-74.1%$73.69M$250K0.0081News CoverageEarnings ReportQNTMQuantum BiopharmaN/A$25.40-8.7%N/AN/A$73.66MN/A-1.58N/AEarnings ReportUpcoming EarningsGap UpSTROSutro Biopharma3.8304 of 5 stars$0.85+2.2%$6.11+623.6%-75.1%$71.37M$62.04M-0.28240News CoverageUpcoming EarningsASRTAssertio1.871 of 5 stars$0.72+0.4%$2.63+263.1%-41.1%$69.25M$124.96M-2.2620News CoverageUpcoming EarningsGNTAGenenta Science2.6046 of 5 stars$3.79+2.3%$25.00+560.5%-11.6%$69.21MN/A0.007News CoverageShort Interest ↑Gap UpPYXSPyxis Oncology2.4016 of 5 stars$1.11+0.5%$9.00+714.5%-68.8%$68.39MN/A-0.6960News CoverageUpcoming EarningsMNOVMediciNova2.7098 of 5 stars$1.35+0.1%$7.00+418.1%+14.3%$67.44MN/A-5.9810Positive NewsAPLTApplied Therapeutics4.0981 of 5 stars$0.47+0.6%$6.10+1,189.6%-92.7%$66.97M$460K-1.1030OTLKOncobiologics2.4594 of 5 stars$2.00-0.7%$9.60+381.2%-74.1%$66.64MN/A-2.1820Upcoming Earnings Related Companies and Tools Related Companies PMVP Competitors ARTV Competitors QNTM Competitors STRO Competitors ASRT Competitors GNTA Competitors PYXS Competitors MNOV Competitors APLT Competitors OTLK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
